Detalhe da pesquisa
1.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301809
2.
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Pigment Cell Melanoma Res
; 33(2): 358-365, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31587511
3.
Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report.
World J Clin Oncol
; 10(10): 350-357, 2019 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31799150
4.
Combined immune therapy grade IV dermatitis in metastatic melanoma.
Asia Pac J Clin Oncol
; 15(4): 262-265, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30809956
5.
Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Asia Pac J Clin Oncol
; 15(1): 26-30, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30426665